ECSP14024250A - USO INTRAUTERINO DE 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA - Google Patents

USO INTRAUTERINO DE 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA

Info

Publication number
ECSP14024250A
ECSP14024250A ECIEPI201424250A ECPI201424250A ECSP14024250A EC SP14024250 A ECSP14024250 A EC SP14024250A EC IEPI201424250 A ECIEPI201424250 A EC IEPI201424250A EC PI201424250 A ECPI201424250 A EC PI201424250A EC SP14024250 A ECSP14024250 A EC SP14024250A
Authority
EC
Ecuador
Prior art keywords
intrauterine
contraception
well
4in3onas
systems containing
Prior art date
Application number
ECIEPI201424250A
Other languages
English (en)
Inventor
Katja Prelle
Lars Röse
Tuula Valo
Reinhard Nubbemeyer
Harri Jukarainen
Norbert Schmees
Henriikka Korolainen
Original Assignee
Poli Nutri Alimentos S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14024250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Poli Nutri Alimentos S A filed Critical Poli Nutri Alimentos S A
Publication of ECSP14024250A publication Critical patent/ECSP14024250A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe el uso intrauterino de 18–metil–15ß,16ߖmetilen–19–nor–20–espirox–4–en–3–onas de la fórmula general (1) en la anticoncepción la terapia ginecológica, así como un sistema intrauterino que contiene compuestos de la fórmula 1.
ECIEPI201424250A 2012-04-23 2014-10-24 USO INTRAUTERINO DE 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA ECSP14024250A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012206652 2012-04-23

Publications (1)

Publication Number Publication Date
ECSP14024250A true ECSP14024250A (es) 2015-12-31

Family

ID=48142002

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201424250A ECSP14024250A (es) 2012-04-23 2014-10-24 USO INTRAUTERINO DE 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA

Country Status (28)

Country Link
US (1) US20150065472A1 (es)
EP (1) EP2841074A1 (es)
JP (1) JP2015514791A (es)
KR (1) KR20150004807A (es)
CN (1) CN104254333A (es)
AR (1) AR090799A1 (es)
AU (1) AU2013254840A1 (es)
BR (1) BR112014026193A2 (es)
CA (1) CA2871003A1 (es)
CL (1) CL2014002836A1 (es)
CO (1) CO7111255A2 (es)
CR (1) CR20140490A (es)
CU (1) CU20140121A7 (es)
DO (1) DOP2014000241A (es)
EA (1) EA201491922A1 (es)
EC (1) ECSP14024250A (es)
HK (1) HK1205000A1 (es)
IL (1) IL235095A0 (es)
IN (1) IN2014DN07839A (es)
MA (1) MA37444A1 (es)
MX (1) MX2014012849A (es)
PE (1) PE20142438A1 (es)
PH (1) PH12014502372A1 (es)
SG (1) SG11201406582XA (es)
TN (1) TN2014000444A1 (es)
TW (1) TW201350122A (es)
UY (1) UY34758A (es)
WO (1) WO2013160213A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015055789A1 (en) * 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90627C (fi) 1992-07-31 1994-03-10 Leiras Oy Laitteisto lääkeainesauvan varustamiseksi vaipalla
PH30867A (en) 1992-07-31 1997-12-09 Leiras Oy Method and equipment for installing a medicine capsule on a support.
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
IL150775A0 (en) * 2000-01-18 2003-02-12 Schering Ag Drospirenone for hormone replacement therapy
NZ585546A (en) * 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
DE102006030416A1 (de) 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
DE102007063495A1 (de) * 2007-12-29 2009-09-17 Bayer Schering Pharma Aktiengesellschaft 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
PH12013500806A1 (en) * 2010-11-08 2013-06-03 Hll Lifecare Ltd A novel intrauterine device with controlled copper release

Also Published As

Publication number Publication date
KR20150004807A (ko) 2015-01-13
US20150065472A1 (en) 2015-03-05
PH12014502372A1 (en) 2015-01-26
BR112014026193A2 (pt) 2017-06-27
TN2014000444A1 (en) 2016-03-30
HK1205000A1 (en) 2015-12-11
EP2841074A1 (de) 2015-03-04
CR20140490A (es) 2014-11-17
WO2013160213A1 (de) 2013-10-31
CN104254333A (zh) 2014-12-31
PE20142438A1 (es) 2015-02-01
JP2015514791A (ja) 2015-05-21
DOP2014000241A (es) 2014-12-31
UY34758A (es) 2013-11-29
AR090799A1 (es) 2014-12-10
TW201350122A (zh) 2013-12-16
IN2014DN07839A (es) 2015-04-24
EA201491922A1 (ru) 2015-04-30
CO7111255A2 (es) 2014-11-10
SG11201406582XA (en) 2014-11-27
AU2013254840A1 (en) 2014-11-06
CU20140121A7 (es) 2014-12-26
IL235095A0 (en) 2014-12-31
CL2014002836A1 (es) 2015-03-13
MA37444A1 (fr) 2016-11-30
CA2871003A1 (en) 2013-10-31
MX2014012849A (es) 2015-02-05

Similar Documents

Publication Publication Date Title
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CR20150629A (es) Compuestos químicos
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CO7111287A2 (es) Composiciones plaguicidas y procesos relacionados
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
GT201400241A (es) "uso de pro-fungicidas de uk-2a para el control de la sigatoka negra"
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CO6640285A2 (es) 5-alquinil-pirimidinas
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY35500A (es) Indazoles sustituidos con heteroarilo
ECSP13012519A (es) Compuestos sustituidos de benzamida
UY35129A (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR088622A1 (es) 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
MX2017007377A (es) Compuestos organicos.
BR112015030308A2 (pt) antagonistas de progesterona de imidazolila
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
MX369290B (es) Inhibidores de fbx03.
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
CO7111255A2 (es) Uso intrauterino de 18-metil-15ß,16ß-,etilen-19-nor-20-espirox-4-en-3-onas, sistemas intrauterinos que contienen 18-metil-15ß,16ß-metilen-19-nor-20-espirox-4-en-3-onas, así como su uso en la anticon-cepción y terapia ginecológica
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
CL2014002857A1 (es) Uso de 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1) en el tratamiento de trastornos con sangrado uterino y hemorragias; sistema intrauterino que comprende 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1).
BR102014007923A8 (pt) sistema nanoestruturado polimérico e seu uso
UA89388U (ru) Применение глюкозамина гидрохлорида как средства, защищающего организм от системного воздействия высоких температур
CR11704S (es) Dispositivo de liberación de química de un contenedor de química